Global 3D Printing Drug 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI03257307

Publication Date:

March 4, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global 3D Printing Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
3D printing drugs can realize the advantages of precise control of drug dosage and precise control of release time, which has become one of the focuses of the pharmaceutical industry. The market potential is huge, so the number of companies entering the industry is increasing.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
3D-printed drugs represent an innovative technology in the pharmaceutical manufacturing sector in recent years, enabling highly personalized medication through the application of 3D printing techniques. The market size has been progressively expanding, especially in the realms of specific patient populations and rare diseases, where the demand for tailored medications is on the rise. By employing 3D printing, drugs can achieve precise dosage and controlled release, thereby enhancing therapeutic efficacy. Looking ahead, as the technology matures further and regulations continue to evolve, 3D-printed drugs are poised to play a significant role in a broader spectrum of disease treatments.
The 鈥�3D Printing Drug Industry Forecast鈥� looks at past sales and reviews total world 3D Printing Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected 3D Printing Drug sales for 2025 through 2031. With 3D Printing Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 3D Printing Drug industry.
This Insight Report provides a comprehensive analysis of the global 3D Printing Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on 3D Printing Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global 3D Printing Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 3D Printing Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 3D Printing Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of 3D Printing Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
ZipDose
MED
FDM
SSE
Other
Segmentation by Application:
Oral Solid Dosage Form
Non-Oral Solid Dosage Form
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Aprecia Pharmaceuticals
Triastek
FabRx
Multiply Labs

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global 3D Printing Drug 麻豆原创 Size (2020-2031)
2.1.2 3D Printing Drug 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for 3D Printing Drug by Country/Region (2020, 2024 & 2031)
2.2 3D Printing Drug Segment by Type
2.2.1 ZipDose
2.2.2 MED
2.2.3 FDM
2.2.4 SSE
2.2.5 Other
2.3 3D Printing Drug 麻豆原创 Size by Type
2.3.1 3D Printing Drug 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global 3D Printing Drug 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 3D Printing Drug Segment by Application
2.4.1 Oral Solid Dosage Form
2.4.2 Non-Oral Solid Dosage Form
2.4.3 Other
2.5 3D Printing Drug 麻豆原创 Size by Application
2.5.1 3D Printing Drug 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global 3D Printing Drug 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 3D Printing Drug 麻豆原创 Size by Player
3.1 3D Printing Drug 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global 3D Printing Drug Revenue by Player (2020-2025)
3.1.2 Global 3D Printing Drug Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global 3D Printing Drug Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 3D Printing Drug by Region
4.1 3D Printing Drug 麻豆原创 Size by Region (2020-2025)
4.2 Global 3D Printing Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas 3D Printing Drug 麻豆原创 Size Growth (2020-2025)
4.4 APAC 3D Printing Drug 麻豆原创 Size Growth (2020-2025)
4.5 Europe 3D Printing Drug 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa 3D Printing Drug 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas 3D Printing Drug 麻豆原创 Size by Country (2020-2025)
5.2 Americas 3D Printing Drug 麻豆原创 Size by Type (2020-2025)
5.3 Americas 3D Printing Drug 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC 3D Printing Drug 麻豆原创 Size by Region (2020-2025)
6.2 APAC 3D Printing Drug 麻豆原创 Size by Type (2020-2025)
6.3 APAC 3D Printing Drug 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe 3D Printing Drug 麻豆原创 Size by Country (2020-2025)
7.2 Europe 3D Printing Drug 麻豆原创 Size by Type (2020-2025)
7.3 Europe 3D Printing Drug 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa 3D Printing Drug by Region (2020-2025)
8.2 Middle East & Africa 3D Printing Drug 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa 3D Printing Drug 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global 3D Printing Drug 麻豆原创 Forecast
10.1 Global 3D Printing Drug Forecast by Region (2026-2031)
10.1.1 Global 3D Printing Drug Forecast by Region (2026-2031)
10.1.2 Americas 3D Printing Drug Forecast
10.1.3 APAC 3D Printing Drug Forecast
10.1.4 Europe 3D Printing Drug Forecast
10.1.5 Middle East & Africa 3D Printing Drug Forecast
10.2 Americas 3D Printing Drug Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 3D Printing Drug Forecast
10.2.2 Canada 麻豆原创 3D Printing Drug Forecast
10.2.3 Mexico 麻豆原创 3D Printing Drug Forecast
10.2.4 Brazil 麻豆原创 3D Printing Drug Forecast
10.3 APAC 3D Printing Drug Forecast by Region (2026-2031)
10.3.1 China 3D Printing Drug 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 3D Printing Drug Forecast
10.3.3 Korea 麻豆原创 3D Printing Drug Forecast
10.3.4 Southeast Asia 麻豆原创 3D Printing Drug Forecast
10.3.5 India 麻豆原创 3D Printing Drug Forecast
10.3.6 Australia 麻豆原创 3D Printing Drug Forecast
10.4 Europe 3D Printing Drug Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 3D Printing Drug Forecast
10.4.2 France 麻豆原创 3D Printing Drug Forecast
10.4.3 UK 麻豆原创 3D Printing Drug Forecast
10.4.4 Italy 麻豆原创 3D Printing Drug Forecast
10.4.5 Russia 麻豆原创 3D Printing Drug Forecast
10.5 Middle East & Africa 3D Printing Drug Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 3D Printing Drug Forecast
10.5.2 South Africa 麻豆原创 3D Printing Drug Forecast
10.5.3 Israel 麻豆原创 3D Printing Drug Forecast
10.5.4 Turkey 麻豆原创 3D Printing Drug Forecast
10.6 Global 3D Printing Drug Forecast by Type (2026-2031)
10.7 Global 3D Printing Drug Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 3D Printing Drug Forecast
11 Key Players Analysis
11.1 Aprecia Pharmaceuticals
11.1.1 Aprecia Pharmaceuticals Company Information
11.1.2 Aprecia Pharmaceuticals 3D Printing Drug Product Offered
11.1.3 Aprecia Pharmaceuticals 3D Printing Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Aprecia Pharmaceuticals Main Business Overview
11.1.5 Aprecia Pharmaceuticals Latest Developments
11.2 Triastek
11.2.1 Triastek Company Information
11.2.2 Triastek 3D Printing Drug Product Offered
11.2.3 Triastek 3D Printing Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Triastek Main Business Overview
11.2.5 Triastek Latest Developments
11.3 FabRx
11.3.1 FabRx Company Information
11.3.2 FabRx 3D Printing Drug Product Offered
11.3.3 FabRx 3D Printing Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 FabRx Main Business Overview
11.3.5 FabRx Latest Developments
11.4 Multiply Labs
11.4.1 Multiply Labs Company Information
11.4.2 Multiply Labs 3D Printing Drug Product Offered
11.4.3 Multiply Labs 3D Printing Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Multiply Labs Main Business Overview
11.4.5 Multiply Labs Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.